Company Overview
Company Type: Public Company
Website: www.ipatherapeutics.com
Number of Employees: 102
Ticker: IPA (NasdaqGM)
Year Founded: 1983


Business Description
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
21.7
Market Capitalization
55.8
TEV/Total Revenue
2.7x
EBITDA
(16.6)
Total Enterprise Value
59.0
TEV/EBITDA
NM
EBIT
(20.2)
Cash & ST Invst.
6.7
P/Diluted EPS Before Extra
NM
Net Income
(20.7)
Total Debt
9.8
Price/Tang BV
9.7x
Capital Expenditure
(1.5)
Total Assets
76.6
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Apr-30-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.14)
(0.14)
(0.56)
-
-
Revenue (mm)
5.85
5.97
23.91
28.13
24.97

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
2.48x

Non-Periodic Estimates

Recommendation
Buy (1.50)
Target Price
10.99
Potential Upside
390.80%


Key Professionals
Name
Title
Bath, Jennifer Lynne
CEO, President & Non-Independent Director
Taylor, Kristin 
Interim Chief Financial Officer
Orton, David E.
Chief Operating Officer
Roodink, Ilse 
Chief Scientific Officer
Romijn, Roland 
Head of General Operations of the Utrecht site of IPA (Europe)
Duplantis, Barry Neil
Vice President of Client Relations

Key Board Members
Name
Title
Kuo, James S.
Independent Chairman of the Board
Bath, Jennifer Lynne
CEO, President & Non-Independent Director
Burke, Robert D.
Independent Director
Buyse, Chris 
Director
Champagne, Guy 
Member of Advisory Board
Helbling, Lisa 
Director
Neame, Dion 
Member of Strategic Advisory Board
Springer, Barry A.
Director
Witters, Dirk 
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
3204–4464 Markham Street | Victoria, BC | V8Z 7X8 | Canada
Phone: 250-483-0308   

Current and Pending Investors
Autumn Spirit OÜ, Ingalls & Snyder, LLC

Prior Investors
NameSilo Technologies Corp. (OTCPK:URLO.F)

Investment Arms
Tanqueray Resources Ltd., Equity Compensation Plan

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.24
Market Cap (mm)
56.1
Open
 2.27
Shares Out. (mm)
25.1
Previous Close
 2.24
Float %
85.9%
Change on Day
0.01
Shares Sold Short (mm)
0.0
Change % on Day
0.6%
Dividend Yield %
-
Day High/Low
 2.29/ 2.13
Diluted EPS Excl. Extra Items
(0.83)
52 wk High/Low
 8.11/ 2.06
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.05
Beta 5Y
0.56


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
NasdaqGM:IPA - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
U-Protein Express B.V.
U-Protein Express B.V. engages in the production and sale of preclinical grade recombinant proteins and recombinant antibodies for the research and pre-clinical applications in Europe and internationally. The company’s products include antibodies, complement proteins, peptides, cytokines, enzymes, hormones, receptors, polyclonal antibodies, and others, as well as recombinants in the areas oncology and haematology. It also provides purification of recombinant proteins, monoclonal and polyclonal antibody generation, and cryostorage and hybridoma sequencing services. The company also sells its products online. It serves biotech and pharma industry, and academia. The company was founded in 2002 and is based in Utrecht, the Netherlands. U-Protein Express B.V. operates as a subsidiary of ImmunoPrecise Antibodies Ltd.

Europe
Life Sciences Tools and Services
-
-
-
Tanqueray Exploration Ltd.
As of December 21, 2016, Tanqueray Exploration Ltd. was acquired by ImmunoPrecise Antibodies Ltd., in a reverse merger transaction. ImmunoPrecise Antibodies Ltd. supplies custom monoclonal and polyclonal antibodies for various species worldwide. It offers monoclonal hybridomas for rabbits, mice, and rats; and polyclonal antibodies for rabbits, rats, goats, and sheep. The company also provides custom peptide production and cryopreservation services. It serves academic, biotech, and pharmaceutical industries. The company was formerly known as Tanqueray Exploration Ltd. and changed its name to ImmunoPrecise Antibodies Ltd. in December 2016. ImmunoPrecise Antibodies Ltd. was incorporated in 1995 and is headquartered in Calgary, Canada.

United States and Canada
Precious Metals and Minerals
0.00
0.00
0.00
0496106 BC Ltd.,

United States and Canada
-
-
-
-
9066-9854 Quebec Inc.
9066-9854 Quebec Inc. operates as a subsidiary of ImmunoPrecise Antibodies Ltd.

United States and Canada
-
-
-
-
ImmunoPrecise Netherlands B.V.
ImmunoPrecise Netherlands B.V. operates as a biotechnology company. The company is based in Oss, the Netherlands. ImmunoPrecise Netherlands B.V. operates as a subsidiary of ImmunoPrecise Antibodies Ltd.

Europe
Biotechnology
-
-
-
ModiQuest Research B.V.
ModiQuest Research B.V. offers antibody therapies and products for biotechnology and pharmaceutical industry. It provides bio-reagents focusing on auto-immune, oncology, and infectious diseases. The company offers antibody discovery generation, antibody research and cloning, polyclonal, and diagnostics development services. ModiQuest Research B.V. was founded in 2004 and is based in Oss, the Netherlands. As of April 6, 2018, ModiQuest Research B.V. operates as a subsidiary of ImmunoPrecise Antibodies Ltd.

Europe
Life Sciences Tools and Services
-
-
-
Talem Therapeutics LLC

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-15-2023
-
Public Offering
Target
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)


60.00
Jul-10-2023
-
Shelf Registration
Target
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)


300.00
Oct-13-2021
-
Public Offering
Target
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)


50.00
Jun-2-2021
-
Shelf Registration
Target
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)


14.74
Feb-3-2021
-
Public Offering
Target
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)


7.82
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-19-2023
Executive Changes - CFO
ImmunoPrecise Antibodies Announces CFO Transition
Sep-14-2023
Earnings Calls
ImmunoPrecise Antibodies Ltd., Q1 2024 Earnings Call, Sep 14, 2023
Sep-06-2023
Executive/Board Changes - Other
ImmunoPrecise Antibodies Ltd. Announces Board Changes
Aug-15-2023
Follow-on Equity Offerings
ImmunoPrecise Antibodies Ltd. has filed a Follow-on Equity Offering in the amount of $60 million.
Aug-09-2023
Investor Activism - Target Communication
ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing

Competitors
AbbVie Inc. (NYSE:ABBV), Abveris Inc., Antibody Solutions Inc., Genovac AG, Genscript Biotech Corporation (SEHK:1548), Johnson & Johnson (NYSE:JNJ), LakePharma, Inc. (Acquired), Novartis AG (SWX:NOVN), Roche Holdings, Inc.


Advisors
Most Recent Auditor
Grant Thornton International Ltd.
Private Placement Advisors
LightPath Capital, Inc., Raymond James Ltd.
Public Offering Advisors
Bennett Jones LLP, Crowe MacKay LLP, Dorsey & Whitney LLP, Grant Thornton LLP, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright US LLP


Most Recent Auditor
Grant Thornton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:30 AM
IPA
Immunoprecise Antibodies Ltd 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 04:42 AM
IPA
ValuEngine Rating and Forecast Report for IPA
Reports
11
CFRA Equity Research

Oct 01, 2023 05:40 PM
IPA
ImmunoPrecise Antibodies Ltd.
Reports
9
MarketLine

Sep 20, 2023 06:01 AM
IPA
ImmunoPrecise Antibodies Ltd
Reports
34
Benchmark Company
Wasserman, Robert Mark
Sep 18, 2023 04:14 AM
IPA
Fiscal 2024 Off to Strong Start as New AI Offerings Gain Traction
Reports
5
H.C. Wainwright & Co.
Ramakanth, Swayampakula
Sep 18, 2023 04:13 AM
IPA
Focus Continues on Synergistic Products and Services; Reiterate Buy
EPS Estimates*
8
S&P Global Compustat

Sep 07, 2023 03:17 AM
IPA
Immunoprecise Antibodies Ltd 2023_09_07
Reports
15
Benchmark Company
Wasserman, Robert Mark
Sep 06, 2023 06:12 AM
IPA
Board Restructured, Majority Replaced After Letter by Largest Holder
Notes
3
H.C. Wainwright & Co.
Ramakanth, Swayampakula
Jul 12, 2023 04:06 AM
IPA
New Revenue Growth Strategy; Reiterate Buy
Reports
8
Benchmark Company
Wasserman, Robert Mark
Jul 11, 2023 04:07 AM
IPA
Strong 4Q23 Sets Up Promising Fiscal 2024
Reports
5


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Van Hyfte, Dirk Medard-Helena

1,565,865

6.25

3.6

Apr-13-2022


Brands, Ingrid Maria-Henri

1,565,865

6.25

3.6

Apr-13-2022


Ingalls & Snyder, LLC

1,060,055

4.23

2.4

Jun-30-2023


BMO Asset Management Corp.

208,110

0.83

0.5

Jun-30-2023


Bath Ph.D., Jennifer Lynne

201,818

0.81

0.5

Sep-22-2023


Smith, Gregory Stuart

73,500

0.29

0.2

Apr-30-2023


Canadian Imperial Bank of Commerce, Asset Management Arm

42,427

0.17

0.1

Jun-30-2023


Citadel Advisors LLC

34,783

0.14

0.1

Jun-30-2023


Burke, Robert D.

31,000

0.12

0.1

Apr-30-2023


Chabot, Frederic 

27,209

0.11

0.1

Apr-20-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Tower Research Capital LLC
7,569
3,853
Chabot, Frederic 
27,209
3,000
Ingalls & Snyder, LLC
1,060,055
2,020
Helbling, Lisa 
2,000
2,000
Bath Ph.D., Jennifer Lynne
201,818
2,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Citadel Advisors LLC
34,783
(110,731)
Maxam Capital Management Ltd.
0
(71,100)
BMO Asset Management Corp.
208,110
(32,870)
Royal Bank of Canada, Banking & Securities Investments
0
(26,170)
Susquehanna International Group, LLP, Asset Management Arm
0
(13,911)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-15
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
ENP Newswire
Sep-14
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
Business Wire
Sep-11
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
ENP Newswire
Sep-06
IPA Announces Board Refreshment
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
Affinity Maturation Services, Antibody Characterization Services, Antibody Development Services, Antibody Engineering Services, B Cell Select, B Cell Sorting, Screening and Sequencing Services, Bi-Specific, Tri-Specific, VHH and VNAR Antibody Manufacturing Services, Bispecific Abthena, Cryopreservation Services, Custom Antigen Modeling, Design and Manufacturing Services, Custom, Immune and Naïve Phage Display Production and Screening Services, DeepDisplay, DNA Cloning, Protein and Antibody Downstream Processing Services, Hybridoma Production Services, Integrated SGI-DNA’s benchtop automated DNA Printer, LucinaTech Humanization Services, Phage Display Services, PolyTope, Purification and Validation Services, Recombinant Mammalian Proteins and Antibodies, Transient and Stable Cell Line Generation Services


Upcoming Events
Date/Time
Type
Nov-09-2023
Shareholder/Analyst Calls
Nov-09-2023
Annual General Meeting
Dec-15-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-26-2023
Sep-22-2023
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEC
6-K
28 KB
Sep-25-2023
Sep-22-2023
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEC
6-K
13 KB
Sep-22-2023
-
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
Notice of the Meeting and Record Date
69 KB
Sep-22-2023
-
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
Material Change Report
111 KB
Sep-21-2023
-
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
News Releases
112 KB
Sep-19-2023
Sep-19-2023
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEC
6-K
16 KB
Sep-18-2023
Sep-15-2023
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEC
6-K
265 KB
Sep-15-2023
-
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
Statement of Executive Compensation
370 KB
Sep-14-2023
-
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
News Releases
251 KB
Sep-14-2023
Jul-31-2023
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
Interim Financial Statements
815 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Roodink, Ilse  (Chief Scientific Officer)
Oct-02-2023
Common Shares
600
1,451
Open Market Acquisition
17.95
Multiple
-
Oct-02-2023
Common Shares
48
116
Open Market Acquisition
-
Exchange Announcement
-
Oct-02-2023
Common Shares
6
15
Open Market Acquisition
-
Exchange Announcement
-
Oct-02-2023
Common Shares
341
824
Open Market Acquisition
-
Exchange Announcement
-
Oct-02-2023
Common Shares
105
254
Open Market Acquisition
-
Exchange Announcement
-
Oct-02-2023
Common Shares
100
242
Open Market Acquisition
-
Exchange Announcement
Bath Ph.D., Jennifer Lynne (CEO, President & Non-Independent Director)
Sep-22-2023
Common Shares
1,000
2,721
Open Market Acquisition
0.50
Multiple
Bath Ph.D., Jennifer Lynne (CEO, President & Non-Independent Director)
Sep-18-2023
Common Shares
1,000
2,596
Open Market Acquisition
0.50
Multiple
Bath Ph.D., Jennifer Lynne (CEO, President & Non-Independent Director)
May-22-2023
Common Shares
950
3,866
Open Market Acquisition
0.48
Multiple
-
May-22-2023
Common Shares
850
3,456
Open Market Acquisition
-
Exchange Announcement
-
May-22-2023
Common Shares
100
410
Open Market Acquisition
-
Exchange Announcement
Chabot, Frederic 
Apr-20-2023
Common Shares
1,000
3,847
Open Market Acquisition
3.82
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Kuo, James S.
Independent Chairman of the Board
(183) 381-1879x7
-

Bath, Jennifer Lynne
CEO, President & Non-Independent Director
1-250-483-0308
-

Burke, Robert D.
Independent Director
250-483-0308
-

Buyse, Chris 
Director
250-483-0308
-

Champagne, Guy 
Member of Advisory Board
1-250-754-1400
-

Helbling, Lisa 
Director
250-483-0308
-

Neame, Dion 
Member of Strategic Advisory Board
250-483-0308
-

Springer, Barry A.
Director
250-483-0308
-

Witters, Dirk 
Director
250-483-0308
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bath, Jennifer Lynne
CEO, President & Non-Independent Director
1-250-483-0308
-

Taylor, Kristin 
Interim Chief Financial Officer
250-483-0308
-

Orton, David E.
Chief Operating Officer
250-483-0308
-
davido@unitywireless.com
Roodink, Ilse 
Chief Scientific Officer
250-483-0308
-

Romijn, Roland 
Head of General Operations of the Utrecht site of IPA (Europe)
250-483-0308
-

Duplantis, Barry Neil
Vice President of Client Relations
250-483-0308
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
